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ABSTRACT 
Objective: The present study was carried out to evaluate if Virgin Coconut Oil (VCO) exerts any protective or regenerative effects on pancreatic β 
cells in Alloxan induced diabetic rats and to observe and determine the morphology of islets of animals from different treatment groups. 
Methods: Twenty six adults male Wistar rats were divided into 4 groups. Group 1 served as a control and received no treatment. Group 2 served as a 
diabetic control where they received 120 mg/kg body weight Alloxan at week 1. Group 3 was administered with Alloxan at 120 mg/kg body weight followed 
by VCO treatment for 10 w. Group 5 was administered with 0.8 ml VCO for 13 w prior to being administered with Alloxan 8 w after VCO treatment.  
Blood glucose readings and body weight were monitored weekly during the treatment period. IPGTT was carried out prior to animal sacrifice. 
Histological analysis was carried out on the pancreas of animals in VCO treated and control groups.  
Results: VCO treated rats were able to reduce hyperglycaemia in diabetic individuals. Histological analysis indicates that VCO was able to 
regenerate damaged islets of diabetic rats and was also able to prolong their survival despite being hyperglycaemic. 
Conclusion: VCO has potential protective and regenerative effects towards diabetic rats and further research should be evaluated to develop a 
probable mechanism of action. 
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INTRODUCTION 
Metabolic balance is governed by blood glucose concentration. 
Diabetes mellitus is a metabolic disorder caused by impaired insulin 
action or release or both and is characterised by the rise in blood 
glucose along with metabolic instabilities [1]. Diabetes represents 
one of the world’s most common diseases, 171 million suffer 
diabetes in the year 2000 and it is estimated to affect 366 million 
people by the year 2030 [2]. 
The search for a safer yet effective anti-diabetic agent in plants has 
become a growing interest in research. Some plants and their 
derivatives have been observed to have anti-hyperglycaemic 
properties [3-5] including VCO.  
Sanskrit records dating back 4000 y have documented coconut 
products in Ayuverdic medical applications to treat ailments ranging 
from receding hairlines to heart problems, whereas it is a remedy for 
at least 69 illnesses in Chinese medicine [6]. Unlike copra oil or 
cooking oil, VCO does not undergo a refining, bleaching and 
deodorising process, as it is already an edible oil. Its production retains 
the biologically active substances naturally found in the water and/or 
milk of the coconut by eliminating or through limited heat, making use 
of enzymatic reactions and fermentation of the coconut milk. VCO 
exists as a clear oil, which has a distinct coconut scent. 
A number of fatty acids were detected [7] within the oil, namely 
caproic, caprylic, capric, lauric, myrustic, palmitic, stearic, oleric and 
linoleic acid with lauric acid holding the highest percentage of about 
47% in VCO [8]. The monolaurins of the fatty acids gives VCO other 
properties such as being an anti-bacterial, anti-fungal as well as anti-
microbial agent by destroying those that have a lipid coating [9]. 
Antioxidant activity and phenolic compounds like Tocophenol and 
Tocotrienol found in VCO aids in prevention of various chronic 
diseases, including cancer and cardiovascular diseases [7]. The 
determination of its antioxidant status showed that defences against 
ROS were increased with VCO and prevented lipid peroxidation [10]. 
The present study was carried out to determine if VCO exerts any 
protective or regenerative effect on pancreatic β cells in Alloxan 
induced diabetic rats and to observe and determine the morphology 
of islets of different groups following different VCO treatments.  
MATERIALS AND METHODS 
Virgin coconut oil preparation 
VCO was prepared according to Hayatullina et al., (2012) with slight 
from localwere sourcedcoconutsMature[11].modifications
markets. After dehusking, its meat was extracted with the use of an 
electric grater. For every 100g of freshly grated coconut flesh, 100g 
wasbefore the mixtureaddedwascoconut waternaturalof
squeezed to give out the coconut milk. The mixture was passed 
through a muslin cloth and fermented for 48 h in an incubator at 37 
°C. After fermentation, 3 layers formed, the first and second layers 
were scooped out and centrifuged at 13500 rpm for 15 min, which 
will give rise to further separation of the oil and curdy layer. The 
clear oil was dried in an oven at 60 °C for 24 h.  
Animals 
26 Wistar rats at 8-10 w age and an average weight ranging between 
230-280g were used in these experiments. Male rats were used in all 
experiments. Only 18 rats survived until the end of the treatment 
period. The animals were kept under standard room conditions and 
fed with standard diet and water ad libitum. The study was 
conducted with the approval of the University Research Ethics 
Committee (approval number UBD/DVC/32.11). 
Treatment protocols 
The rats were randomly distributed, selected and placed into 4 
different groups of varying treatments. Weekly measurements of 
blood glucose and weight were recorded and an Intraperitoneal 
Glucose Tolerance Test (IPGTT) was done at the end of the 
experiment. After 10 or 13 w of treatment, the rats were culled and 
the pancreases were harvested. 
Experimental procedure  
The experimental rats were divided into the following four groups. 
The number of animals at the start of the experiments (total 24 
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animals) are indicated in each treatment group. Only a total of 18 
animals survived until the end of the experiments.  
• Group 1 (n=4) -served as a control and received no treatment. 
• Group 2 (n=4) -served as a diabetic control and received 
diabetic induction at a dose of 120 mg/kg body weight Alloxan at 
initial week. 
• Group 3(n=8) -received diabetic induction at a dose of 120 
mg/kg body weight Alloxan at initial week and VCO treatments 
thrice weekly on alternate days for 10 w at a dose of 0.8 ml. 
• Group 5 (n=10) -received VCO treatments three times weekly 
on alternate days for 13 w at a dose of 0.8 ml and received diabetic 
induction at a dose of 120 mg/kg body weight Alloxan at week 8. 
Diabetes induction 
Alloxan was prepared by dissolving Alloxan monohydrate (Sigma, 
USA) with 0.9% standard saline solution. Prior to Alloxan 
administration, the rats were left to fast overnight with access to 
water ad libitum. A single intraperitoneal injection of Alloxan at 120 
mg/kg body weight was administered. Blood glucose readings were 
taken after 72 h following alloxan administration. 
Blood glucose and body weight 
Blood glucose readings and body weight were recorded on a weekly 
basis. Blood was withdrawn from tail vein and glucose levels were 
measured using a single touch glucometer (Style Free Optium, Abbot 
Diabetes Care Ltd.). A blood glucose reading of > 6.1 mmol/l was 
considered diabetic while a reading of >13.8 mmol/l was considered 
to be severely diabetic [3].  
Intraperitoneal glucose tolerance test (IPGTT) 
The IPGTT was tested in overnight fasted (16 h) rats. Fasting blood 
glucose readings were taken from the tail vein before glucose 
administration and at 15, 30, 60, 90 and 120 min after glucose 
administration (2 g/kg body weight via intraperitoneal injection) 
and measurements of glucose levels were taken using single touch 
glucometer (Style Free Optium, Abbot Diabetes Care Ltd.) 
Histological analysis 
The rats were culled via carbon dioxide asphyxiation and pancreas 
tissue was collected. The pancreas were fixed in 3.7% formaldehyde 
solution (Fluka). Fixed tissue was processed routinely by paraffin 
embedding followed by staining with hematoxylin.  
Statistical analysis 
All data were expressed as mean±SEM. Statistical analysis of body 
weight and blood glucose data was performed by using a Post-Hoc 
Games-Howell test using SPSS 19.0 for statistical comparisons 
involving differences among different experimental groups. For 
comparisons between the starting and end points in the same group 
treatments a T-test of unequal variance was carried out. P values of 
less than 0.05 were considered significant.  
RESULTS 
The effects of VCO on body weight  
The effect of VCO on the body weight of Alloxan induced rats are 
summarized in table 1. The changes in the body weight of the rats 
showed a progressive increase in all the groups except the animals 
in the control untreated groups which showed no significant 
difference (fig. 2). The mean body weight of animals in group 1, 3, 4 
and 5 at week 10 showed a significant increase compared to their 
body weight at week 1. Animals in group 1, 3, 4 and 5 have a mean 
body weight of 280.5 g, 277.5 g, 215.3 g and 336.3 g on the 5thweek 
while at the 10th 
Effect of VCO on blood glucose 
week of study, they were found to be 348.5 g, 297.3 
g, 207.7 g and 296.8 g respectively (Group 2; table 1). 
The effects of VCO on the blood glucose of Alloxan induced diabetic 
rats are summarised in table 1. Table 1 shows the changes of blood 
glucose levels for normal untreated rats, control Alloxan only 
treated rats and diabetic rats during the 10 w treatment period. 
Following Alloxan injections, the mean±SEM of blood glucose 
concentration before VCO administration was 5.02, 25.7, 25.85, 
26.37, and 5.425 mmol/l in normal untreated, control Alloxan only, 
regenerated group and VCO protection group.  
The measurements of individuals that have survived until 10 w 
were considered. The Regeneration group gave two distinct 
results and therefore we have separated these animals into two 
subgroups, which are Regeneration Recovering (Group 3) which 
contain diabetically induced animals that have undergone VCO 
treatments for 10 w and shown recovery and Regeneration 
Hyperglycaemic (Group 3A) which contain diabetically induced 
animals that have undergone VCO treatments for 10 w but 
remained hyperglycaemic. 
The effect of VCO showed a gradual reduction of blood glucose levels 
in animals in the Regeneration Recovering (Group 3), previously at 
25.85 mmol/l had significantly reduced (fig. 1) to 10.93 mmol/l 
following 10 w of VCO administration. However, the animals in 
Regeneration Hyperglycaemic (Group 3A) showed no reduction of 
blood glucose levels, retaining a hyperglycaemic state at the 
maximum reading of 27.9 mmol/l. 
The animals in Protection (Group 5) indicated that earlier 
administrations of VCO gave no effect in reducing hyperglycaemia 
after alloxan induction at 8 weeks. Blood glucose level of animals at 
5 w at 5.5 mmol/l had significantly increased (fig. 1) to 20.65 
mmol/l at 10 w (table 1). 
 
 
Fig. 1: Graph showing mean IPGTT blood glucose readings 
(mmol/l) of treated animal groups vs time (min) 
 
Histological analysis  
Histological analysis on islet structure revealed a significant 
difference between both diabetic control Group 2 (fig. 3) and Group 
5 (fig. 6A) in comparison to the islets found in Group 1 (fig. 2A). 
There was no significant difference in the number and shape of islets 
between the diabetic group (Group 3) in fig. 4A-C and Group 1. 
Conversely, diabetic Group 3A (fig. 5A) showed less number of islets 
than that of diabetic islets in Group 3.  
We observed that the control untreated rats (Group 1) showed the 
normal pancreatic islet structure (fig. 2A). In contrast, pancreatic 
sections of alloxan induced diabetic rats (Group 2) revealed islets 
that were comparatively smaller in size and have a shrunken 
appearance, exhibiting how islet cells have degenerated (hydropic 
degeneration) and necrotised (fig. 3A). 10 w of VCO treatment on 
diabetic rats (Group 3) revealed that some sections have 
regenerated islet cells (fig. 5A) despite these animals remaining 
hyperglycaemic (Group 3A) at the end of the study. Pancreatic 
sections of previously diabetic recovered animals that have 
recovered from hyperglycaemia (Group 3) indicated that the islet 
morphology was near normal in appearance with round nuclei and 
abundant cytoplasm (fig. 4A-C) and are similar in comparison to 
the islets from animals in the control group (fig. 2A). Nevertheless, 
light hydropic degeneration and necrosis was evident in the islet 
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cells of diabetic Group 3A (fig 5A), however the damage towards 
the islets was not as severe as those found in control Alloxan only 
group (fig. 3A), only exhibiting a slightly vacuolated cytoplasm. 8 
w of VCO treatment prior to ablation by alloxan failed to show any 
protective effects against substantial islet damage, however, we 
note that the extent of severity of islet damage was less compared 
to that of the alloxan only control group (fig. 3A). 
 
 
Fig. 2: Intact islets from normal non-Alloxan treated rats 
 
Fig. 3: Islet features from an alloxan induced diabetic rat 




Fig. 4: Microscopic features of alloxan induced diabetic rat with 
10 w of VCO treatment and recovering from hyperglycaemia 
 
Table 1: Table showing mean±SEM values of blood glucose (mmol/l) and body weight (g) of groups after 10 w of treatment 
Group Blood glucose (mmol/l) Weight (g) 
Week 1 Week 5 Week 10 Week 1 Week 5 Week 10 
1 (n=4) 5.025±0.2926 5.4±0.559 4.9±0.434 265.5±7.772 280.5±0.412 348.5±12.86** 
2 (n=3) 25.7±2.233 27.9 20.13±0.933 242±6.245 235±8.185 237.3±7.126 
3 (n=4) 25.85±1.461 20.9±2.664 10.93±2.822* 253.3±3.902 277.5±10.137 296.8±8.230** 
3A (n=3) 26.37±1.533 27.9 25.3±1.501 244.3±5.170 215.3±10.975 297.3±14.77** 
5 (n=4) 5.425±0.225 5.5±0.137 20.65±2.095 232±5.774 336.3±8.443 207.7±6.438** 
*P<0.05 for when comparing blood glucose against control (C) group, **P<0.05 when comparing body weights inweek1 and week 10 of animals in 
the same group. 
 
 
Fig. 5: Microscopic features of alloxan induced diabetic rat with 
10 w of VCO treatment that remained hyperglycaemic 
 
Fig. 6: Islet features of alloxan induced rat followed by 
treatment of VCO for 13 w  
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DISCUSSION 
Our study indicates that VCO has blood glucose lowering properties 
as evident from the blood glucose lowering effects observed in 
recovered individuals following Alloxan treatment. Alloxan treated 
diabetic animals which have recovered were able to respond to the 
glucose challenge when subjected to IPGTT, approaching blood 
glucose levels comparable to that of normal non-treated animals 
(Group 1). Histopathological analysis revealed that their islets were 
recovering when compared to Alloxan only treated animal islets (fig. 
3A). Histological results showing normal, healthy islets indicate that 
VCO was able to reverse oxidative damage towards islet cells (fig 4A-
C). Furthermore, VCO is rich in fatty acids which is correlated to 
insulin resistance [13]. Medium chained fatty acids (MCFA) present 
does not accumulate in skeletal muscle and promote resistance [14] 
but is rather easily metabolised and used by cells. It is suggested that 
surviving cells benefitted from the MCFA for cell recovery. Due to 
the recovery of the cells, normal β-cell functions was able to resume 
as denoted by IPGTT and diabetic symptoms of such as weight loss 
have been alleviated. 
However, the diabetic rat group (Group 3A) did not share similar 
results. IPGTT (fig. 1) revealed that the rats were unable to achieve 
normal β-cell functions and remained hyperglycaemic. Histological 
reports nevertheless revealed islet cells, which appear to be 
recovering (fig. 5A). The damage of the cells was not as extensive as 
those in the control group (Group 2). It was noted that despite being 
permanently hyperglycaemic, the rats had persevered, which 
suggests VCO increasing their chances of survival. 
Animals that were subjected to 8 w of VCO treatment and then 
followed by beta cell ablation with a single intraperitoneal injection 
of Alloxan showed that there was no protective effect exerted from 
the VCO treatment regime. However, we do note that the severity of 
islet damage was less severe.  
Histological evaluation indicated that the islets had undergone necrosis 
although the severity of the damage observed was less compared to 
sections belonging to animals in the diabetic control (Group 2) (fig. 3A). 
The recovery of animals in the VCO treated group from their 
hyperglycaemic state could be attributed to the expansion of the islets 
via the increase in the numbers of beta cell via multiplication or its 
regeneration. An increase in the number of beta cells would provide an 
adequate supply of insulin during the 10 w regenerative period. We 
present alternative evidence that VCO is involved in regenerative 
capabilities of the beta cells in addition to previous studies which 
attribute its blood glucose lowering effects due to its antioxidant 
properties [12]. The possible involvement of VCO to increase 
proliferation of beta cell numbers demands further investigation.  
CONCLUSION 
Based on our findings, it is suggested that VCO is able to suppress and 
reduce the severity of hyperglycaemia and islet damage in Alloxan 
induced diabetic rats. Further research on VCO may reveal its potential 
to be further developed into an anti-diabetic drug or potential treatment 
for diabetic patients.  
Since our results indicate VCO to have an ameliorative effect on 
regenerating pancreatic islets while also having a favourable effect on 
blood glucose levels, it implies VCO to be beneficial in managing and 
preventing diabetes mellitus.  
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